RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
7.70
-0.49 (-5.98%)
Dec 3, 2024, 11:39 AM EST - Market open
RedHill Biopharma Revenue
RedHill Biopharma had revenue of $1.29M in the quarter ending June 30, 2024, a decrease of -28.40%. This brings the company's revenue in the last twelve months to $3.71M, down -89.63% year-over-year. In the year 2023, RedHill Biopharma had annual revenue of $6.53M, down -89.43%.
Revenue (ttm)
$3.71M
Revenue Growth
-89.63%
P/S Ratio
1.73
Revenue / Employee
$69,943
Employees
53
Market Cap
9.86M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.53M | -55.27M | -89.43% |
Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Streamline Health Solutions | 20.30M |
ImmunoPrecise Antibodies | 17.44M |
Dominari Holdings | 12.59M |
MSP Recovery | 10.73M |
Evogene | 7.48M |
PAVmed | 4.03M |
Immuron | 3.27M |
RDHL News
- 1 day ago - RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court - PRNewsWire
- 5 weeks ago - RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND - PRNewsWire
- 6 weeks ago - RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury - PRNewsWire
- 7 weeks ago - RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment - PRNewsWire
- 2 months ago - RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians - PRNewsWire
- 2 months ago - RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 - PRNewsWire
- 3 months ago - RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - PRNewsWire
- 3 months ago - RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire